Abstract
The risk of thromboembolic events must be balanced against the risk of bleeding while using warfarin as an anticoagulant. Time in therapeutic range (TTR) is an important assessment for evaluating the quality of anticoagulation treatment because it has been proven to be associated with fewer bleeding and thromboembolic events. In Malaysia, the pharmacist-managed anticoagulant Medication Therapy Adherence Clinic (AC-MTAC) service is used for follow-up and dosage control of warfarin. This is the first report of TTR, bleeding, and thromboembolic events in the year 2020.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
